Stay updated on FG-4592 and Rosiglitazone Interaction Clinical Trial
Sign up to get notified when there's something new on the FG-4592 and Rosiglitazone Interaction Clinical Trial page.

Latest updates to the FG-4592 and Rosiglitazone Interaction Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedFooter/site-wide updates include the addition of 'Revision: v3.3.3' and the removal of 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'; these changes do not affect the study page content or its data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check47 days agoChange DetectedRevision label in the page footer updated from v3.2.0 to v3.3.2 as part of a platform update; no changes to study details or primary content.SummaryDifference0.1%

- Check55 days agoChange DetectedRemoved the government funding notice banner at the top of the page, reducing operational notices shown to users. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check76 days agoChange DetectedUI updates have changed the page layout, header, and styling, while the core study details such as title, conditions, eligibility criteria, and interventions remain the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check97 days agoChange Detected- Added a government-operation notice and status links, clarifying potential delays and current NIH Clinical Center openness. - Removed the previous version tag (v3.1.0) and introduced v3.2.0.SummaryDifference7%

- Check105 days agoChange DetectedPage version updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.2%

Stay in the know with updates to FG-4592 and Rosiglitazone Interaction Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FG-4592 and Rosiglitazone Interaction Clinical Trial page.